Stay updated with breaking news from Roch Houot. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory (R/R) large B-cell lymphoma who are ineligible to undergo a transplant.
Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.
SANTA MONICA - Kite, a Gilead Company , today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen...
– Yescarta Achieved a Complete Metabolic Response of 71% at 3 Months Versus 12% Expected with Historical Standard of Care Controls – – Results Published in Nature Medicine– ...
(RTTNews) - Kite, the cell therapy unit of Gilead Co. (GILD), announced Monday positive results from the Phase 2 ALYCANTE study for use of its chi...